Oscar Health (OSCR)
(Real Time Quote from BATS)
$21.94 USD
-0.39 (-1.75%)
Updated Sep 24, 2024 12:08 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Income Statements
Fiscal Year end for Oscar Health, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 5,863 | 3,964 | 1,839 | 463 | 488 |
Cost Of Goods | 4,642 | 3,281 | 1,624 | 309 | 408 |
Gross Profit | 1,221 | 683 | 215 | 153 | 80 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,456 | 1,273 | 759 | 556 | 339 |
Income After Depreciation & Amortization | -236 | -590 | -544 | -402 | -259 |
Non-Operating Income | -7 | 2 | -21 | 0 | 0 |
Interest Expense | 25 | 23 | 5 | 4 | 0 |
Pretax Income | -267 | -610 | -571 | -406 | -259 |
Income Taxes | 3 | -1 | 1 | 1 | 2 |
Minority Interest | 0 | -3 | 1 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -271 | -610 | -571 | -407 | -261 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -271 | -606 | -573 | -407 | -261 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -234 | -571 | -522 | -388 | -259 |
Depreciation & Amortization (Cash Flow) | 2 | 18 | 23 | 14 | 0 |
Income After Depreciation & Amortization | -236 | -590 | -544 | -402 | -259 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 221.66 | 212.48 | 178.97 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.22 | -2.85 | -3.20 | NA | NA |
Diluted Net EPS (GAAP) | -1.22 | -2.85 | -3.20 | -4.72 | NA |
Fiscal Year end for Oscar Health, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 2,219.34 | 2,142.31 | 1,431.66 | 1,439.99 | 1,521.54 |
Cost Of Goods | 1,708.72 | 1,554.77 | 1,205.24 | 1,163.19 | 1,182.00 |
Gross Profit | 510.62 | 587.53 | 226.42 | 276.80 | 339.54 |
SG&A, R&D, and Dept/Amort Expenses | 442.81 | 401.97 | 371.90 | 335.04 | 346.07 |
Income After SG&A, R&D, and Dept/Amort Expenses | 67.81 | 185.56 | -145.48 | -58.24 | -6.53 |
Non-Operating Income | -0.87 | -1.18 | 1.05 | -0.41 | -1.61 |
Interest Expense | 5.99 | 5.90 | 6.22 | 6.13 | 6.12 |
Pretax Income | 60.95 | 178.48 | -150.64 | -64.79 | -14.26 |
Income Taxes | 4.64 | 1.00 | -0.81 | 0.92 | 1.16 |
Minority Interest | 0.11 | 0.11 | 0.19 | -0.31 | 0.10 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 56.31 | 177.48 | -149.84 | -65.70 | -15.43 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 56.21 | 177.37 | -150.03 | -65.40 | -15.53 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 303.97 | 293.80 | 227.08 | 223.10 | 219.40 |
Diluted EPS Before Non-Recurring Items | 0.20 | 0.62 | -0.66 | -0.29 | -0.07 |
Diluted Net EPS (GAAP) | 0.20 | 0.62 | -0.68 | -0.29 | -0.07 |